Abstract 2306: BLU-222, an investigational, potent, and selective CDK2 inhibitor, demonstrated robust antitumor activity in <i>CCNE1</i>-amplified ovarian cancer modelsVictoria E. Brown, Yoon Jong Choi, Jian Guo et al.|Cancer Research|2022Cited by 13
Abstract 1279: Development of a selective CDK2-E inhibitor in CCNE driven cancersYoon Jong Choi, Marion Dorsch, Steve Wenglowsky et al.|Cancer Research|2021Cited by 7